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Abstract
Background: Analysis of Cerebrospinal Fluid (CSF) samples holds great promise to diagnose neurological
pathologies and gain insight into the molecular background of these pathologies. Proteomics and metabolomics
methods provide invaluable information on the biomolecular content of CSF and thereby on the possible status of
the central nervous system, including neurological pathologies. The combined information provides a more
complete description of CSF content. Extracting the full combined information requires a combined analysis of
different datasets i.e. fusion of the data.
Results: A novel fusion method is presented and applied to proteomics and metabolomics data from a pre-clinical
model of multiple sclerosis: an Experimental Autoimmune Encephalomyelitis (EAE) model in rats. The method
follows a mid-level fusion architecture. The relevant information is extracted per platform using extended canonical
variates analysis. The results are subsequently merged in order to be analyzed jointly. We find that the combined
proteome and metabolome data allow for the efficient and reliable discrimination between healthy, peripherally
inflamed rats, and rats at the onset of the EAE. The predicted accuracy reaches 89% on a test set. The important
variables (metabolites and proteins) in this model are known to be linked to EAE and/or multiple sclerosis.
Conclusions: Fusion of proteomics and metabolomics data is possible. The main issues of high-dimensionality and
missing values are overcome. The outcome leads to higher accuracy in prediction and more exhaustive description
of the disease profile. The biological interpretation of the involved variables validates our fusion approach.
Background
The omics fields hold huge promises in the investigation
of various diseases. Multiple examples are available in
the literature showing the potential of proteomics [1,2]
and metabolomics [3]. Both domains carry valuable
information about biological pathways involved in
human diseases [4,5]. Proteomics aims to provide a
comprehensive identification and quantification of pro-
teins present in tissues or biofluids. This information
allows one to find networks of cellular mechanisms and
to get more insight into molecular disease processes [6].
Metabolomics aims to determine the small molecule fin-
gerprints of cellular processes. Similarly to proteomics,
metabolomics relies on the detection and quantification
of small biomolecules, here metabolites. The proteome
and metabolome separately and in combination repre-
sent an instant picture of a biological system [7].
The proteome and metabolome are not disjoint. Pro-
tein levels obviously influence the metabolic profile, e.g.
through enzymatic reactions. On the other hand, the
metabolites concentrations may affect the expression of
proteins [8]. Therefore, the combination of this informa-
tion in a systems biology approach is expected to pro-
vide a more comprehensive understanding of biological
entities [9]. Various studies have been proposed to ana-
lyse jointly different metabolomics or proteomics data in
order to improve the overall understanding of the sys-
tem [10,11]. Our aim is here to propose a new statistical
approach. The objective of this method is to perform
data fusion of multiple types of measurements related to
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the same biological system. We chose a proteomics and
metabolomics platform that measured the very same
CSF samples. This biofluid is in close interaction with
the Central Nervous System (CNS). Therefore, CSF can
be expected to reflect the status of the CNS. This
assumption has been used to study neurological diseases
such as Multiple Sclerosis (MScl) [12]. MScl is an auto-
immune disease and the most common cause of neurolo-
gical disability in young adults [13]. It manifests itself as
an acute, focal, inflammatory demyelination and axonal
loss with limited remyelination. The disease culminates
in chronic multifocal sclerotic plaques. The associated
symptoms are various and follow an unpredictable
course. The CSF samples are relatively accessible. How-
ever, collecting samples from large cohorts of MScl
patients and healthy volunteer is still a complex and time
consuming task. Moreover, the analysis of such clinical
samples often encounters challenges related to the varia-
tion linked to genetic and environmental background.
In the frame of biomarker discovery, it is therefore
more straightforward and productive to initiate an
investigation from an animal model of the disease. The
Experimental Autoimmune Encephalomyelitis (EAE)
model is one of the most intensively studied model of
autoimmune disease [14]. EAE, like MScl is an inflam-
matory disorder of CNS. It is mainly used to look at the
neuroinflammatory mechanism, which is one of the key
hallmarks of MScl. This animal model has been repro-
duced in many species, including rats [15]. Depending
on the species and antigen used, the resulting EAE pre-
sents a specific disease course. The acute version of this
model, as used in this study, is induced by the injection
of Complete Freund Adjuvant (CFA) and Myelin Basic
Protein (MBP). The initial symptom, paralysis of the tip
of the rat’s tail, appears after approximately 10 days.
This ultimately culminates in paralysis extended up to
the limbs. The 10th day can be considered as the onset
of disease. Our main interest in this study is to define
the combined proteomic and metabolomic biomarker
pattern corresponding to this onset. An experimental
design has been constructed to characterize the disease
at this time point. The aim is to establish whether these
combined biomarkers and/or biomarker profiles can act
as predictive indicators of the onset of disease.
The main objective from a data analysis point of view
is to extract from both proteome and metabolome all
the relevant information allowing a comprehensive defi-
nition of the disease profile. It is also of the utmost
importance to extract information from both platforms.
Indeed a shared pattern would provide insights on inter-
actions between proteins and metabolites. This informa-
tion could greatly enhance our comprehension of the
disease process. For this purpose, we propose a so-called
mid level fusion architecture [16] based on two layers.
The first layer aims to extract all the information allow-
ing for discrimination between control and disease sam-
ples per platform. This step is hampered by the usual
“curse of dimensionality”, as it will be shown in the next
section. The second layer is designed to fuse the infor-
mation of each platform. At this point, a new problem
arises related to missing measurements from platform to
platform. To solve these practical problems, we propose
a solution based on two methods: extended Canonical
Variates Analysis (eCVA) [17] and a modified version of
Principal Component Analysis (PCA) [18]. These two
methods and our data analysis strategy are described in
the methods section. The fusion method is then applied
to the analysis of metabolomics and proteomics data of
the EAE experiment. The outcome of this approach
allows for a better description of the data of the joint
platforms than the one achieved by using the data from
the two platforms separately. The variables driving the
model are then explored in term of biological meaning.
This allows confirming the validity of our approach. In
addition, it is possible to visualize the EAE biomarker
profile on the systems biology level.
Methods
Material
Induction of Acute EAE in Lewis rat
Male Lewis rats (Harlan Laboratories B.V., the Nether-
lands) kept under normal housing conditions with water
and food ad libitum, weighing between 175 and 225
grams at the start of the experiment, were inoculated on
day 0 as previously described [19]. Briefly, a 100 μL saline
based emulsion containing 50 μL Complete Freund Adju-
vant H37 RA (CFA, Difco Laboratories, Detroit, MI), 500
μg Mycobacterium tuberculosis type H37RA (Difco) and
20 μg guinea pig Myelin Basic Protein (MBP) was injected
subcutaneously in the pad of the left hind paw of Isoflur-
ane anaesthetized animals. Next to these MBP challenged
rats, referred to as the EAE group, two control groups
were included: a group of animals receiving the same
emulsion without MBP (CFA group) and a healthy group
undergoing anesthesia only (Healthy group). Each group
consisted of 15 animals. The animals present in one given
cage were all belonging to the same group. The animals
were sacrificed to collect CSF on day 10 (day of onset in
the EAE group). The design is summarized in Table 1.
Table 1 Experimental Design of EAE model
Treatment
day 0
Groups
number
Number of
animals
Effects
Anesthesia
only
1 15 Healthy
CFA 2 15 Peripheral Inflammation
CFA+MBP 3 15 Neuroinflammation (EAE) +
peripheral inflammation
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Animals were housed per 3 and cages were rando-
mized across treatments and disease duration. Disease
symptoms and weights of all animals were recorded
daily. The animal experiments described were approved
by the local Institutional Animal Care and Use
Committee.
CSF sampling
On day 10, animals were euthanized with CO2/O2.
Terminal CSF samples were obtained by direct insertion
of an insulin syringe needle (Myjector, 29 G × 1/2”) via
the arachnoid membrane into the Cisterna Magna. For
this purpose a skin incision was made followed by a
horizontal incision in the musculus trapezius pars des-
cendens to reveal the arachnoid membrane. A volume of
maximum 60 μL was collected per animal. Each sample
was centrifuged within 20 min after sampling, for 10
min at 2000 g at 4°C. After centrifugation the superna-
tants were stored at -80°C for further analysis. Previous
experiments have shown that collecting up to 60 μL
using this technique and conditions provided hemoglo-
bin-free CSF samples measured by ESI-Orbitrap. As an
additional check fresh samples, supernatant and pellet
size were visually scored for hemolysis and samples
were discarded if positive.
From the set of 45 samples, 3 of them (from different
groups) were contaminated with blood and were
excluded from measurements.
Measurements
MS-Orbitrap: samples preparation and data acquisition
10 μL of rat CSF sample was put into a 96-microtiter-
well plate (Nunc low binding, VWR, The Netherlands),
and 20 μL of 0.2% Rapigest (Waters, Milford, MA) in 50
mM ammonium bicarbonate buffer was added to each
well. After a 30 min incubation period with 1,4-dithio-
threitol (60°C) and, subsequently, iodoacetamide (37°C),
4 μL of 0.1 μg/μL gold-grade trypsin (Promega, Madi-
son, WI)/3 mM Tris-HCl (pH 8.0) was added to each
sample. The samples were incubated overnight at 37°C.
To adjust the pH of the digest to pH < 2, a high con-
centration of trifluoroacetic acid was added to the mix-
ture prior to a final incubation step at 37°C for a
duration of 45 minutes to stop the digestion reaction.
Mass spectrometry measurements were carried out on
a Ultimate 3000 nano LC system (Dionex, Germering,
Germany) online coupled to a hybrid linear ion trap/
Orbitrap MS (LTQ Orbitrap XL; Thermo Fisher Scienti-
fic, Germany). 5 μL digest were loaded onto a C18 trap
column (C18 PepMap, 300 μm ID × 5 mm, 5 μm parti-
cle size, 100 Å pore size; Dionex, The Netherlands) and
desalted for 10 minutes using a flow rate of 20 μL/min
0.1% TFA. Then the trap column was switched online
with the analytical column (PepMap C18, 75 μm ID ×
150 mm, 3 μm particle and 100 Å pore size; Dionex,
The Netherlands) and peptides were eluted with the fol-
lowing binary gradient: 0%-25% solvent B for 120 min
and 25%-50% solvent B for a further 60 minutes, where
solvent A consist of 2% acetonitrile and 0.1% formic in
water and solvent B consists of 80% acetonitrile and
0.08% formic acid in water. The column flow rate was
set to 300 nL/min. For MS detection a data dependent
acquisition method was used: high resolution survey
scan from 400-1800 Th. was performed in the Orbitrap
(value of target of automatic gain control AGC 106,
resolution 30,000 at 400 m/z; lock mass was set to
445.120025 u (protonated (Si(CH3)2O)6) [20]). Based on
this survey scan the 5 most intensive ions were consecu-
tively isolated (AGC target set to 104 ions) and fragmen-
ted by collision-activated dissociation (CAD) applying
35% normalized collision energy in the linear ion trap.
After precursors were selected for MS/MS, they were
excluded for further MS/MS spectra for 3 minutes.
Following a standardized noise reduction procedure,
the Orbitrap raw files were preprocessed using the Pro-
genesis LC-MS software package (version 2.5, Nonlinear
Dynamics, Newcastle-upon-Tyne, United Kingdom). In
this software package all peaks in the raw files are
aligned according to their retention time by a graphical
detection algorithm. This algorithm detects the peptide
peaks in a gel-view representation of the mass spectro-
metry data and matches corresponding peaks (termed as
features in this software package) between samples.
Strict criteria for alignment acceptance were employed
(at least 200 corresponding peaks per sample for the
sample to be included in subsequent analysis steps). Fol-
lowing this, peptides were identified and assigned to
proteins by exporting features, for which MS/MS spec-
tra were recorded, using the Bioworks software package
(version 3.2; Thermo Fisher Scientific, Germany; peak
picking by Extract_msn, default settings). The resulting.
mgf file was submitted to Mascot (version 2, Matrix
Science, London, United Kingdom) for identification to
interrogate the UniProt-database (version 57.0, taxon-
omy (Rattus norvegicus): 7114 sequences). Only ions
with charge states between +2 and +7 were considered
and only proteins with at least two unique peptides
(Mascot sore > 25) assigned to them were accepted as
true identifications. Carbamidomethylation of cysteine
was set as fixed and oxidation of methionine as variable
modification allowing a maximum of 2 missed cleavages.
Mass tolerance for precursor ions was set to 10 ppm
and for fragment ions at 0.5 Da. The cut-off for mass
differences between the measured and the theoretical
mass of the identified peptides was set at 2 ppm. The
Mascot search results were imported back into the Pro-
genesis software to link the identified peptides to the
detected abundances of these peptides. The data were
exported subsequently in Excel format. In this exported
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excel file an abundance (area-under-the-curve) is listed
for all features (and consequently all identified peptides
and proteins) in all individual samples. The abundance
is used instead of the peak intensity to account for tail-
ing of the peptide peaks during the LC-separation. The
differences in abundance are subsequently used for ana-
lysis of the differences between the groups for all identi-
fied peptides and proteins.
NMR: samples preparation and data acquisition
10 μL of rat CSF were thawed at room temperature and
240 μL D2O were added to biofluid in order to obtain
the sufficient amount of sample for NMR measurement.
We used TSP-d4 (99 at.%D) as an internal standard for
chemical shift reference (δ 0.00 ppm) and metabolite
quantification. For the latter, 25 μL of 8.8 mM TSP-d4
stock solution in D2O was added to 250 μL of rat CSF
to a final concentration of 0.8 mM TSP. The TSP-d4
stock was prepared by weighing in dry TSP-d4. The pH
of the CSF was adjusted to around 7 (7.0 - 7.1) by add-
ing phosphate buffer (9.7 μL 1 M, to a final concentra-
tion of 35 mM). The final CSF NMR sample (284.7 μL)
was then transferred to a SHIGEMI microcell NMR
tube for NMR measurements.
The 1D 1H NMR spectra of rat CSF samples were
acquired on an 800 MHz Inova (Varian) system
equipped with a 5 mm triple-resonance, Z-gradient
HCN cold-probe. Suppression of water was achieved by
using WATERGATE (delay: 85 μs). For each 1D 1H
NMR spectrum 512 scans of 18 K data points were
accumulated with a spectral width of 9000 Hz. The
acquisition time for each scan was 2 s. Between scans, a
8 s relaxation delay was employed. Prior to spectral ana-
lysis, all acquired Free Induction Decays (FIDs) were
zero-filled to 32 K data points, multiplied with a 0.3 Hz
line broadening function, Fourier transformed, manually
phase and the TSP internal reference peak was set at 0
ppm - by using ACD/SpecManager software. The set of
42 rat CSF spectra were acquired and preprocessed as
described above. However due to high line broadening
of internal standard (TSP) two spectra were not
included in spectral analysis. In total 40 spectra were
subsequently transferred to Matlab, version 7.6 (R2008b)
(Mathworks, Natick, MA) for further analysis.
The NMR spectral data is then preprocessed, which
typically involves baseline correction, alignment, bin-
ning, normalization and scaling. Baseline correction of
NMR spectra was performed by applying Asymmetric
Least Square method [21]. Fluctuation in experimental
conditions like sample temperature, pH and ionic
strength can lead to chemical shift variations, therefore
NMR spectra were aligned by using improved para-
metric time warping [22]. A further problem is the high
dimensionality of the data (circa 10000 variables). It is
common to apply binning to this kind of data which
reduces the number of variables. To perform proper
spectral bucketing we used adaptive intelligent binning
[23]. This binning procedure, more complex than the
classical binning, ensures that peaks are not divided
over multiple bins. Moreover it allows excluding regions
without signals from the analysis. The chemical shift
range δ 0.75 - 4.15 was used for binning procedure
because it contained most relevant information. This
region was selected based on visual inspection of the
spectra because it contains signals with high signal to
noise ratio. Next, spectral resonances corresponding to
one identified metabolite were summed and regrouped
in one bin. This procedure was applied to the reso-
nances were no overlapping was present and it led to
153 bins in total. The identification of the metabolites
was performed using Chenomx (Edmonton, Canada).
For the purpose of making spectra comparable as the
final step of the preprocessing approach integral nor-
malization was applied to the binned data.
The analysis proposed in this work is initiated by an
exploratory analysis. The objective here is to assess the
quality of the two data sets and detect outliers. The
fusion itself is performed afterwards. Both steps are
detailed below, respectively.
Exploratory method
The different data sets have been analyzed using explora-
tory methods in order to detect outliers. This also pro-
vides some insights on the information content of the
data sets and eventually their ability to provide relevant
information related to the separation of the groups. For
this purpose, Principal Component Analysis (PCA) [24]
and robust PCA [25] have been used. The outliers detec-
tion has been based on cut off values on both orthogonal
and Mahalanobis distances, as proposed in [26].
Mid-level fusion
The purpose of data fusion is to extract the information
spread across the different platforms. Conclusions based
on multiple independent types of measurement are
more reliable than from one platform alone (assuming
that each type of measurement is relevant to the investi-
gated problem). More importantly it may provide new
scientific insights on relations between compounds such
as protein-metabolite interactions. The simplest
approach is to concatenate the different data sets in a
low-level fusion approach [16]. However this strategy is
greatly affected by the variability between the two plat-
forms. Therefore we designed a mid-level architecture
capable to discriminate between a number of before-
hand defined groups. The mid-level fusion analysis con-
tains two steps as presented in Figure 1.
Two problems have to be faced during the analysis of
the two -omics data set. The first one has to deal with a
dimensionality problem. Indeed both metabolomics and
proteomics studies measured a large number of variables
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on relatively few samples. The second challenge is
related to the missing values. Each instrumental plat-
form received the same samples. However, some mea-
surements had to be excluded from the study because of
instrumental artifacts or technical issues during the
measurement. Therefore the algorithm has to deal with
two different problems. In the two following sections we
provide answers for each challenge. Finally, we discuss
how to integrate these two steps and how to interpret
the final results.
First step: extended Canonical Variate analysis
The first step consists of extracting and compressing the
information contained in each data set. PCA [27] is the
most usual way to compress data [28]. However,
biological data are often affected by multiple sources of
variance. Therefore, we opted for a “LDA-like” (Linear
Discriminant Analysis) method. The advantage of this
approach is to focus only on the information related to
the defined classes (here the different groups of rats).
Yet such methods are confronted with the “curse of
dimensionality”. Indeed LDA requires more samples
than the variables, otherwise the inversion of the within-
group covariance matrix becomes impossible. A recently
proposed algorithm provides a solution. Extended Cano-
nical Variate Analysis (eCVA) [17,29] has been devel-
oped to cope with multi-collinear data. The concept of
this method very much resembles Fisher LDA. Assum-
ing a data matrix X (n × p) where g groups of ni
eCVA
eCVA
PCA
X1
“Super” loading
(representing the 
importance of each CV)
1st step
2nd step
Prediction
g-1
g-1
X2
T1
T2
T1 T2
n
n
p1
p2
n
n
CV1
CV2
g-1
g-1
p1
p2
n
2 (g-1) PT
Tn
2 (g-1)
b)
a)
Figure 1 Architecture of the mid-level fusion analysis employed here on two data sets X1and X2. The same n samples are divided in g
groups. a) eCVA is applied on each data set to determine the Canonical Variates CV1and CV2allowing the best discrimination and the
corresponding scores T1and T2. b) The scores are merged and analyzed using PCA. The global scores T and super loadings P
Tare obtained. Class
prediction is obtained based on T.
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samples are present, the within-group covariance matrix
Swithin is defined as:
Swithin =
1(
n − g)
g∑
i=1
ni∑
j=1
(
xij − xi
)(
xij − xi
)′
(1)
and the between-group Sbetween is:
Sbetween =
1(
g − 1)
g∑
i=1
(xi − x)(xi − x)′ (2)
where xij is the jth sample in the ith group, xi is the
mean vector in the ith group, and x is the overall mean
vector. The best discrimination between the groups is
obtained by defining a direction w maximizing the ratio
of the between-group on thewithin-group covariances
[28]:
J(w) =
w’Sbetweenw
w’Swithinw
(3)
When Swithin is non-singular, the equation (3) can be
rewritten in the form of an eigenvalue problem:
Sbetweenwa = λa Swithinwa (4)
where a represents the number of directions, la are
the eigenvalues and wa the eigenvectors. Equation (4)
has a maximum dimensionality of a = min(p,g-1).
Therefore even in the case of high dimensional data, the
number of canonical variables extracted is equal to the
number of groups minus one (g-1). It can be shown that
this problem (equation (4)) can be turned into a regres-
sion problem [17]. Partial Least Squares (PLS) method is
then used to solve the equation (5) corresponding to
this regression problem:
Y = Sbetween B + F (5)
where Y contains the differences (xi − x) , the col-
umns of B are wa and F is a residual matrix. The scores
T can then be calculated projecting them along the
directions wa i.e. the canonical variates (CV). The classi-
fication model is then constructed using these scores.
Note that the best results where obtained on vast scaled
data [30] (compared to autoscaled, Pareto scaled and
mean centered data).
The two data sets here have very different dimensions.
The proteomics data set contains almost 50 times more
variables than the metabolomics data. Therefore an
additional variable selection step was introduced for the
proteomics platform. The eCVa model was constructed
on 7114 variables. The 153 most important variables
were selected and used to reconstruct the eCVA model.
The latter is then used in the rest on the analysis.
Second step: Principal Component Analysis for missing
values
The information related to groups has been compressed
by eCVA into a small set of (g-1) canonical variates.
Therefore, the problem of dimensionality does not apply
anymore in the second step. The experimental design is
such that the same samples should be measured by all
platforms. In practice some samples were either missing
or the obtained measurements were detected as outliers
during the exploratory analysis. As a consequence, some
data points are missing in the concatenation of T1 and
T2. It is important to note that this problem does not
arise in the previous step because the different eCVA
models are constructed per platform. Therefore, if a
sample is missing it is simply excluded from the con-
struction of the eCVA model. One should note that the
quantity of missing data should not unbalance dramati-
cally the number of samples per group (this was not
observed in the described data). However, if this strategy
is applied in the second step a considerable amount of
information would remain unused (the samples mea-
sured by one platform but not the other). A method
able to deal with missing values must therefore be used.
We propose an adaptation of the PCA based on the
missing toolbox from Claus Andersson [31,32]. The
missing elements are replaced by model estimates of
these elements. The estimates are iteratively improved
until a convergence criterion is fulfilled and the esti-
mates do not change significantly. The influence of the
missing values on the model is then limited [33,34].
Validation - Interpretation
The method proposed here explicitly uses class informa-
tion. A risk of overfitting exists; therefore a validation
procedure has to be implemented. A test set is con-
structed using 20% of the samples. The test samples
must be representative of the whole set. They are
selected using Kennard and Stone algorithm [35]. The
test samples are then inputted in the eCVA model and
then projected in the PC space. The prediction can be
obtained using an approach similar to Principal Compo-
nent Discriminant Analysis. Once validated, the model
is reconstructed using all available samples.
The biological interpretation is performed by assessing
the importance of the original variables. It is calculated
by multiplying the canonical variates from the first step
by the loadings of the PCA (second step). For example
the weights of the original variables from the first plat-
form are calculated as follow:
w1 = P:,1:g−1.CVT1 (6)
Where w1 contains the weights of the original vari-
ables for the global model (i.e. loadings) P:,1:g-1 contains
the importance of the g-1 first latent variables. The
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same operation can be done for the second platform
using the corresponding g-1 latent variables. The model
can be inspected using a score plot and/or biplot.
The most important variables are then put into con-
text by projecting them into a correlation network. This
network is constructed by calculating all pair-wise Pear-
son correlations rx1x2 in the different classes:
rx1x2 =
ni∑
k=1
(x1k − x1)(x2k − x2)
(ni − sx1sx2 )
(7)
Where ni is the number of samples, x1 and x2 are the
sample means of x1 and x2 whilesx1 and sx2are the stan-
dard deviations of x1 and x2. The complete network is
too large and complex to be used. Therefore a sub-net-
work is represented using the most important variable
as a seed which is expanded to all variables with a cor-
relation superior to 0.8 (in absolute value) to them. The
network is visualized using Graphviz [36,37] where each
node represents one variable. The node is a square if it
represents a variable seen as important by the fusion
method, otherwise as an ellipse.
Results
Explorative analysis
The analysis of the data can be performed first per plat-
form. This is particularly relevant during the exploratory
analysis. PCA was used to visualize each dataset and
detect eventual outliers. In Figure 2 score plots obtained
for both platforms are presented. The samples are
colored in accordance to their group memberships. One
can observe that the separation is clearer for the proteo-
mic platform than for the metabolomics. Indeed in Figure
2a the main source of variance (PC1 explaining 25.5% of
the variance) allows one to separate most of the disease
group (blue circles) from the control samples (in red for
healthy and in green for inflamed animals). Interestingly,
the PC2 also shows separation of two groups of points.
This source of variation represents 15% of the variance.
However, it does not correspond to the experimental
design. This separation is then certainly due to either bio-
logical or instrumental variations. In this case the separa-
tions in two subgroups correspond to two series of
measurements. This effect could be corrected for with
dedicated method [38]. However the proposed fusion
method should be generic enough to deal with this issue.
Therefore we did not investigate further batch effects.
The equivalent plot for the metabolomics platform is
presented in Figure 2b. Here no instrumental variations
are observed but the disease group is also strongly over-
lapping with the control samples.
The most straightforward approach for data fusion is to
analyze the two data sets together. This is called low-level
fusion [16]. It is expected that the two types of informa-
tion should complete each other and improve the class
separation. This low level fusion provides disappointing
results, as can be seen in Figure 3. The two data sets are
analyzed together, using PCA for missing values. The
three classes are overlapping in the plane defined by PC1
and PC2 (explaining 64% of the variance).
Both instrumental analyses provide different informa-
tion about the group separation. However, in both cases
the biological or instrumental variations distort the pic-
ture. The explorative analysis of both sets as one unique
data matrix does not provide a better but actually a
worse separation of the groups. In that respect it is rele-
vant to use a supervised method in order to extract the
relevant information from each data set. This can be
a)
b)
Figure 2 PCA score plot obtained on a) proteomics data and
b) metabolomics data after autoscaling. The healthy and
inflammation controls are represented as red squares and green
triangles. The disease samples are in blue circles. The dotted line in
a) represent the separation between the two batches of
measurements.
Blanchet et al. BMC Bioinformatics 2011, 12:254
http://www.biomedcentral.com/1471-2105/12/254
Page 7 of 12
performed using mid-level fusion as described in the
methods section.
Mid-level fusion
Our approach is based on two steps. The first one con-
sists of a supervised analysis of each platform. After the
first step, each submodel (i.e. per platform) can be
assessed in terms of complexity and prediction, based
on a cross validation included in eCVA. Here the inner
PLS loop of the eCVA models for the proteomics and
metabolomics platforms are using respectively 4 and 8
latent variables. As additional check, we perform the
prediction of the test samples left out during the con-
struction of the eCVA models. They were correctly pre-
dicted in 78% of the cases by the proteomic platform
and in 78% by the metabolomics platform. The latent
variables constructed by eCVA are inspected in order to
determine whether the variability spanned by the latent
variables from one model is comparable to the one
spanned by the other model. The latent variables
obtained for each platform are then concatenated. The
newly formed matrix can be analyzed using PCA. The
test samples groups can be predicted using a method
similar to Principal Component Discriminant Analysis
(PCDA) [39]. The fusion leads to 89% of correct classifi-
cation on the validation set.
Since the model shows good predictive ability we con-
sider it as statistically validated. The model is recon-
structed using all available samples before starting
interpretation. The resulting model can be graphically
assessed using a score plot as shown in Figure 4 where
each sample is color coded according to the groups’
label. The separation of the healthy control (in red)
from the two other groups can be seen along PC1. The
disease and inflammation groups are mostly separated
from each other along PC2 with some overlap. It is
interesting to note that the spread of the disease group
is larger than the other groups. It suggests that this
group is more heterogeneous. Part of the neuroinflam-
mation group is overlapping with the peripheral inflam-
mation group. This would suggest that the neurological
symptoms are delayed for the corresponding animals.
The most significant metabolites and proteins linked
to the disease group are then studied. The selection
rules for proteins were that at least three peptides must
show similar behavior (for example up or down regula-
tion in the disease group). Their importance is then
averaged. The importance is a relative measure of the
influence of the variable on the definition of the group
considered (i.e. the projection of the loading on the vec-
tor defined by the mean of the group). In Table 2 a
selection of the names of main variables, the corre-
sponding Uniprot/CAS numbers and their relative
importance to define this group is listed. The sign of
these values indicates whether the metabolite/protein
concentration is up or down regulated in the disease
group in comparison to the controls. The values have
been normalized in such way that the most important
variable (Hemopexin) has a value of 1.
The interpretation can obviously be based on an uni-
variate approach i.e. considering each selected variable
separately. However, the interest of fusion is to make a
connection between the two types of information and to
Figure 3 Score plot obtained on the concatenation of the
proteomics and metabolomics data sets after autoscaling and
PCA. The healthy and inflammation controls are represented in red
and green. The disease samples are in blue. The three classes
overlap completely.
Figure 4 PCA score plot allowing the visualization of the
results of the fusion of proteomics and metabolomics
platforms. The samples are color-coded according to group labels:
in red squares the healthy control, in green triangles the
inflammation group and in blue circles the disease group.
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evaluate the link between proteins and metabolites. To
facilitate the interpretation of the results we constructed
a correlation network that embodies the interconnec-
tions between the protein and metabolite variations.
The result is presented in Figure 5. Each node corre-
sponds to one metabolite or one protein. The links
between nodes indicate that a correlation is superior to
0.8 (or inferior to -0.8). The complete network is too com-
plex to be reproduced in a single image. The Figure 5
represents a portion of the complete correlation network
centered on hemopexin and T-kininogen 1 i.e. the variable
seen as most important (see Table 2). Only the proteins
and metabolites directly correlated to hemopexin or
T-kininogen 1 or through one other variable are repre-
sented. The correlation network is clearly different
between the disease and control groups. The correlations
observed in the healthy control are represented by solid
black line. The correlations observed in the disease group
are represented by dotted lines.
Discussion
A fingerprint of the EAE onset is defined by our data
analysis approach. The first aspect to be discussed is the
statistical performance of our method. The obtained
results show better prediction ability than individual
analysis and low level fusion based on either eCVA or
Partial Least Squares Discriminant Analysis (PLS-DA)
(see the additional file 1). The limitations of this
approach are mostly related to the statistical aspects.
Firstly, the underlying concept of both eCVA and PCA
is that the information is related to linear variations. In
the cases of more complex signals (non linear
responses), the obtained discrimination could be too low
or based only on a part of the metabolites and proteins
really involved. Secondly, the number of samples mea-
sured by both platforms should be sufficiently high to
ensure that the relations observed are not artifacts.
The second aspect to be discussed is the nature of the
variables selected. One can glean from Table 2 that both
proteins and metabolites participate in the discrimina-
tion model. Apparently the fingerprint of the EAE onset
is better defined using both proteomics and metabolo-
mics knowledge i.e. using a systems biology approach.
In terms of biological interpretation, the obtained results
are coherent with previous studies. Indeed the proteins
presented in Table 2 have been previously linked to EAE
and/or MScl. Increased levels of hemopexin and T-kinino-
gen 1 have been previously reported in neurological disor-
ders [40-42]. The expression level of the kininogen 1
receptor has been proposed as a non-specific index of dis-
ease activity in MScl by Prat et al. [43]. Serum albumin
[41,42] is known to cross the blood brain barrier after
administration of CFA and, in absence of inflammatory
cells in the CNS, albumin is not triggering any neuroin-
flammation [44]. However, we observed reduced level of
albumin in the disease group. This suggests a relation
between the neuroinflammation process and the serum
albumin present in the CNS. However this observation
needs to be validated. Complement C3 [45-48] and Com-
plement C4 [45,49] have been related to MScl. In addition
the Complement C3 and its derived fragments have been
marked as a central player in the pathophysiology of EAE
[50]. Increased concentration of Haptoglobin has been
found in MScl [45]. It has been suggested that Haptoglo-
bin plays a modulatory and protective role on autoim-
mune inflammation of the CNS [51]. Ceruloplasmin
[41,45,52] and citrate [53] are known to rise in concentra-
tion during the inflammation phase. Similarly some of the
selected metabolites have been ascribed to MScl. Increased
lysine level is known to have an impact on the entry of
arginine in leucocytes and thus on the NO synthesis [54].
Table 2 Selection of metabolites and proteins up or
down regulated in the disease group
Name UniProt/CAS
registration number
Importance to define
disease group
Hemopexin P20059 1.00
δ 2.22633 -0.82
T-kininogen 1 P01048 0.80
Serum albumin P02770 -0.68
T-kininogen 2 P08932 0.67
Complement
C3
P01026 0.67
Serotransferrin P12346 0.66
Haptoglobin P06866 0.58
Ceruloplasmin P13635 0.50
Acetone 67-64-1 -0.49
Succinate 110-15-6 -0.46
δ 3.63769 -0.34
Glyceric acid 473-81-4 0.33
Glutamine 56-85-9 -0.32
Valine 72-18-4 -0.32
Sucrose 57-50-1 -0.29
Glyceric acid 473-81-4 0.29
Complement
C4
P08649 0.29
δ 2.24436 -0.28
δ 2.32502 -0.26
Citrate 77-92-9 0.25
δ 4.0078 0.25
δ 4.01128 0.24
3-
hydroxybutyrate
625-72-9 -0.23
Lysine 56-87-1 0.23
Pantothenate 79-83-4 -0.22
Unidentified signals are reported using chemical shift (δ).
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The complete biological interpretation of this multivariate
model requires larger discussion and validation. These
aspects are not in scope of this manuscript and will not be
discussed for brevity reasons.
Figure 5 gives a more global view of the problem.
First, one finds that the correlation network is changed
by the disease. Therefore we decided to focus on two of
the selected variables (Hemopexin and T-kininogen 1)
and the variables directly correlated to them. Here one
can observe that multiple correlations to T kininogen 1
appear in the disease group. This would indicate that
the normal pathways are changed and a new pathway
involving T kininogen 1 as central player and a number
of metabolites (e.g. lactate or inositol) and proteins (e.g.
Complement C3 or Ceruloplasmin) is either created or
becoming preeminent.
Conclusions
The feasibility of fusion of multiple omics platforms was
discussed in this work. The study of the onset of EAE
was chosen as a case study. From the point of view of
data analysis multiple challenges had to be addressed.
The first one had to do with the biological variation
usually encountered in omics experiments. The method
proposed here focuses on the information of interest
through a training procedure. However, the high dimen-
sionality of the data is problematic for discriminant
methods. This explains why it is necessary to use eCVA,
since this method is able to handle highly collinear mul-
tivariate data. The second difficulty is linked to the mul-
tiplatform aspect of this work: the same samples have
been measured by two platforms. In the process some
measurements were either lost or discarded for multi-
ples reasons (missing samples, instrumental problems,
contamination, and outliers). We propose to apply in
the last step of the fusion a version of PCA which is
able to cope with missing values.
Overall the results of the fusion show a significantly
better discrimination of the three classes (disease,
healthy control and inflammation control) compared to
Figure 5 Correlation network centered on hemopexin (P20059) and T-kininogen 1 (P01048). The two first layers of correlation are
represented. The correlations observed in the healthy control samples are represented by solid black line, the ones in the disease group by
dotted lines.
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individual analysis of the two data sets. A second advan-
tage here is the possibility of studying the correlation
between proteomics and metabolomics without having
to assume any model (such as the ones based on known
pathways). For that purpose, we propose the use of cor-
relation networks. The variables seen as important for
any discriminant model can be put in context using this
approach. The obtained networks give an insight about
the modification of the metabolic pathways by the
disease.
From a biological point of view the selected variables
appears to make sense. The proteins and metabolites
described in this study were previously found in rela-
tionship to the EAE and Mscl and therefore provide a
biological validation for the fusion of data from two dif-
ferent platforms. Performing a fusion of several plat-
forms can further confirm the role of the described
pathways and potentially highlight new pathways
involved in the EAE disease process. Future work will
focus on the search and interpretation of newly detected
metabolites and proteins. The pattern defined by these
variables must also be studied by itself and put into the
context of system biology.
Additional material
Additional file 1: Supplementary Material. The low level fusion has
been investigated and is presented in the additional file 1 together with
the effect of block scaling. The comparison between results of eCVA and
Partial Least Squares - Discriminant Analysis is also provided in this
document.
List of abbreviations
CFA: Complete Freund Adjuvant; CNS: Central Nervous System; CSF:
Cerebrospinal Fluid; eCVA: extended Canonical Variates Analysis; LDA: Linear
Discriminant analysis; MScl: Multiple Sclerosis; MBP: Myelin Based Protein;
NMR: Nuclear Magnetic Resonance; PCA: Principal Component Analysis.
Acknowledgements and Funding
This work was performed within the framework of Dutch Top Institute
Pharma, project “The CSF proteome/metabolome as primary biomarker
compartment for CNS disorders” (project nr. D4-102).
Author details
1Radboud University Nijmegen, Institute for Molecules and Materials,
Heyendaalseweg 135, 6524 NP Nijmegen, The Netherlands. 2Abbott
Healthcare Pharmaceuticals Nederland B.V., C.J. van Houtenlaan 36, 1381 CP
Weesp, The Netherlands. 3Department of Neurology, Erasmus University
Medical Center Rotterdam, Dr. Molewaterplein 50, 3015 GE Rotterdam, The
Netherlands.
Authors’ contributions
This study was designed by AA, TT, TL, SSW, and LMCB. The protocol related
to the EAE experiment was designed by AA and TT. The animal experiments
were carried out by AA, HvA and ES. The NMR measurement protocol was
designed by AS, KA and SSW. The sample preparation, NMR measurements
and data processing were made by AS. The Orbitrap measurement protocol
was designed by MS and TL. The sample preparations, Orbitrap
measurements, and data preprocessing were made by MS. The fusion
method presented here was developed and applied by LB. The redaction of
this manuscript was done by LB, AS and MS. LMCB, AA, SSW and TL have
been involved in the critical revision of the manuscript. All authors read and
approved the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Received: 3 January 2011 Accepted: 22 June 2011
Published: 22 June 2011
References
1. Silberring J, Ciborowski P: Biomarkers discovery and clinical proteomics.
TrAC Trend anal Chem 2010, 29(2):128-140.
2. Chambers G, Lawrie L, Cash P, Murray GI: Proteomics: a new approach to
the study of disease. J Pathol 2000, 192(3):280-288.
3. Gowda GAN, Zhang S, Gu H, Asiago V, Shanaiah N, Raftery D:
Metabolomics-based methods for early disease diagnostics. Expert Rev
Mol Diagn 2008, 8(5):617-633.
4. van der Greef J, Stroobant P, van der Heijden R: The role of analytical
sciences in medical systems biology. Curr Opin Chem Biol 2004,
8(5):559-565.
5. Ibrahim SM, Gold R: Genomics, proteomics, metabolomics: what is in a
word for multiple sclerosis? Curr Opin Neurol 2005, 18(3):231-235.
6. Kanehisa M, Goto S: KEGG: Kyoto Encyclopedia of Genes and Genomes.
Nucleic Acids Res 2000, 28(1):27-30.
7. Pearson H: Meet the human metabolome. Nature 2007,
446(7131):8-8.
8. Ghoumari AM, Ibanez C, El-Etr M, Leclerc P, Eychenne B, O’Malley BW,
Baulieu EE, Schumacher M: Progesterone and its metabolites increase
myelin basic protein expression in organotypic slice cultures of rat
cerebellum. J Neurochem 2003, 86(4):848-859.
9. Kitano H: Systems Biology: a brief overview. Science 2002,
295(5560):1662-1664.
10. Dumas M-E, Canlet C, Debrauwer L, Martin P, Paris A: Selection of
biomarkers by a multivariate statistical processing of composite
metabonomic data sets using multiple factor analysis. J Prot Res 2005,
4(5):1485-1492.
11. Thomas CE, Ganji G: Integration of genomic and metabonomic data in
systems biology - are we ‘there’ yet? Curr Opin Drug Disc Dev 2006,
9(1):92-100.
12. Kaddurah-Daouk R, Krishnan RR: Metabolomics: a global biochemical
approach to the study of central nervous system diseases.
Neuropsychopharmacology 2009, 34(1):173-186.
13. Compston A, Coles A: Multiple Sclerosis. Lancet 2008, 372(9648):1502-1517.
14. Baxter AG: The origin and application of experimental autoimmune
encephalomyelitis. Nat Rev Immunol 2007, 7(11):904-912.
15. Lipton MM, Freund J: Encephalomyelitis in the rat following
intacutaneous injection of the central nervous system tissue with
adjuvant. Proc Soc Exp Biol NY 1952, 81(2):260-261.
16. Roussel S, Bellon-Maurel V, Roger J-M, Grenier P: Fusion of aroma, FT-IR
and UV sensor data based on the Bayesian inference. Application to the
discrimination of white grapes varieties. Chemom Intell Lab Syst 2003,
65(2):209-219.
17. Norgaard L, Bro R, Westad F, Engelsen SB: A modification of canonical
variates analysis to handle highly collinear multivariate data. J Chemom
2006, 20(8):425-435.
18. Hastie T, Tibshirani R, Friedman J: The elements of statistical learning:
data mining, inference and prediction. New York: Springer; 2001.
19. Hendriks JJA, Alblas J, Van Der Pol SMA, Van Tol EAF, Dijkstra CD, De
Vries HE: Flavonoids influence monocytic GTPase activity and are
protective in experimental allergic encephalitis. J Exp Med 2004,
200(12):1667-1672.
20. Olsen JV, de Godoy LMF, Li G, Macek B, Mortensen P, Pesch R, Makarov A,
Lange O, Horning S, Mann M: Parts per million mass accuracy on an
orbitrap mass spectrometer via lock mass injection into a C-trap. Mol Cell
Proteomics 2005, 4(12):2010-2021.
21. Eilers PHC: Parametric time warping. Anal Chem 2004, 76(2):404-411.
22. Bloemberg TG, Gerretzen J, Wouters HJP, Gloerich J, van Dael M,
Wessels HJCT, van den Heuvel LP, Eilers PHC, Buydens LMC, Wehrens R:
Improved parametric time warping for proteomics. Chemom Intell Lab
Syst .
Blanchet et al. BMC Bioinformatics 2011, 12:254
http://www.biomedcentral.com/1471-2105/12/254
Page 11 of 12
23. De Meyer T, Sinnaeve D, Van Gasse B, Tsiporkova E, Rietzschel ER, De
Buyzere ML, Gillebert TC, Bekaert S, Martins JC, Van Criekinge W: NMR-
based characterization of metabolic alterations in hypertension using an
adaptive, intelligent binning algorithm. Anal Chem 2008,
80(10):3783-3790.
24. Krzanowski WJ: Principles of Multivariate Analysis. Oxford: Oxford
university press; 2000.
25. Hubert M, Engelen S: Robust PCA and classification in biosciences.
Bioinformatics 2004, 20(11):1728-1736.
26. Hubert M, Rousseeuw P, van der Branden K: ROBPCA: A new approach to
robust principal component analysis. Technometrics 2005, 47(1):64-79.
27. Vandeginste BGM, Buydens LMC, de Jong S, Lewi PJ, Smeyers-Verbeke J,
Massart DL: Handbook of Chemometrics and Qualimetrics: Handbook of
Chemometrics and Qualimetrics: Part B. Amsterdam: Elsevier; 199820.
28. Brown SD, Tauler R, Walczak B, eds: Comprehensive Chemometrics.
Amsterdam: Elsevier; 2009.
29. Norgaard L, Soletormos G, Harrit N, Morten A, Olsen O, Nielsen D,
Kampmann K, Bro R: Fluorescence spectroscopy and chemometrics for
classification of breast cancer samples-a feasibility study using extended
canonical variates analysis. J Chemom 2007, 2007(10):451-458.
30. Keun HC, Ebbels TMD, Antti H, Bollard ME, Beckonert O, Holmes E,
Lindon JC, Nicholson JK: Improved analysis of multivariate data by
variable stability scaling: application to NMR-based metabolic profiling.
Anal Chim Acta 2003, 490(1-2):265-276.
31. Andresson CA, Bro R: The N-way toolbox for MATLAB. Chemom Intell Lab
Syst 2000, 52(1):1-4.
32. Missing toolbox. [http://www.models.life.ku.dk/source/].
33. Andersson CA, Bro R: Improving the speed of multi-way algorithms: Part
I. Tucker 3. Chemom Intell Lab Syst 1998, 42(1-2):93-103.
34. Walczak B: Dealing with missing data. Part I. Chemom Intell Lab Syst 2001,
58(1):15-27.
35. Kennard RW, Stone LA: Computer aided design of experiments.
Technometrics 1969, 11(1):137-148.
36. Opgen-Rhein R, Strimmer K: From correlation to causation networks: a
simple approximate learning algorithm and its application to high-
dimensional plant gene expression. BMC Syst Biol 2007, 1:37.
37. Graphviz - Graph Visualization Software. [http://www.graphviz.org/].
38. Draisma HHM, Reijmers TH, van der Kloet F, Bobeldik-Pastorova I, Spies-
Faber E, Vogels JTWE, Meulman J, Boomsma DI, van der Greef J,
Hankemeier T: Equating, or correction for between-block effects with
application to body fluid LC-MS and NMR metabolomics data sets. Anal
Chem 2010, 82(3):1039-1046.
39. Lavine BK, Rayens WS: Statistical Discriminant Analysis. In Comprehensive
Chemometrics. Volume 3. Edited by: Brown SD, Tauler R, Walczak B.
Amsterdam: Elsevier; 2009:517-540.
40. Rithidech KN, Honikel L, Milazzo M, Madian D, Troxell R, Krupp LB: Protein
expression profiles in pediatric multiple sclerosis: potential biomarkers.
Mult Scler 2009, 15(4):455-464.
41. Liu T, Donahue Kc, Hu J, Kurnellas MP, Grant JE, Li H, Elkabes S:
Identification of differentially expressed proteins in experimental
autoimmune encephalomyelitis (EAE) by proteomic analysis of the
spinal cord. J Prot Res 2007, 6(7):2565-2575.
42. Hammack BN, Fung KYC, Hunsucker SW, Duncan MW, Burgoon MP,
Owens GP, Gilden DH: Proteomic analysis of multiple sclerosis
cerebrospinal fluid. Mult Scler 2004, 10(3):245-260.
43. Prat A, Biernacki K, Saroli T, Orav JE, Guttman CRG, Weiner HL, Kroury SJ,
Antel JP: Kinin B1 receptor expression on multiple sclerosis mononuclear
cells: Correlation with magnetic resonance imaging T2-weighted lesion
volume and clinical disability. Arch Neurol 2005, 62(5):795-800.
44. Rabchevsky AG, Degos J-D, Dreyfus PA: Peripheral injections of Freund’s
adjuvant in mice provoke leakage of serum proteins through the blood-
brain barrier without inducing reactive gliosis. Brain Res 1999, 832(1-
2):84-96.
45. Dumont D, Noben J-P, Raus J, Stinissen P, Robben J: Proteomic analysis of
cerebrospinal fluid from multiple sclerosis patients. Proteomics 2004,
4(7):2117-2124.
46. Jongen PJH, Doesburg WH, Ibrahim-Stappers JLM, Lemmens WAJG,
Hommes OR, Lamers KJB: Cerebrospinal fluid C3 and C4 indexes in
immunological disorders of the central nervous system. Acta Neurol
Scand 2000, 101(2):116-121.
47. Gay FW: Early cellular events in multiple sclerosis Intimations of an
extrinsic myelinolytic antigen. Clin Neurol Neurosurg 2006, 108(3):234-240.
48. Stoop MP, Dekker LJ, Titulaer MK, Burgers PC, Sillevis Smitt PAE, Luider T,
Hintzen RQ: Multiple sclerosis related proteins identified in CSF by
advanced mass spectrometry. Proteomics 2008, 8(8):1576-1585.
49. Ingram G, Hakobyan S, Robertson NP, Morgan BP: Elevated plasma C4a
levels in multiple sclerosis correlate with disease activity. J Neuroimmunol
2010, 223(1-2):124-127.
50. Barnum SR, Szalai AJ: Complement and demyelinating disease: No MAC
needed? Brain Res Rev 2006, 52(1):58-68.
51. Galicia G, Maes W, Verbinnen B, Kasran A, Bullens D, Arredouani M,
Ceuppens JL: Haptoglobin deficiency facilitates the development of
autoimmune inflammation. Eur J Immunol 2009, 39(12):3404-3412.
52. Hunter MIS, Nlemadim BC, Davidson DLW: Lipid peroxidation products
and antioxidant proteins in plasma and cerebrospinal fluid from
multiple sclerosis patients. Neurochem Res 1985, 10(12):1645-1652.
53. Sinclair AJ, Viant MR, Ball AK, Burdon MA, Walker EA, Stewart PW, Rauz S,
Young SP: NMR-based metabolomic analysis of cerebrospinal fluid and
serum in neurological diseases - a diagnostic tool? NMR Biomed 2010,
23(2):123-132.
54. Li P, Yin Y-L, Li D, Kim SW, Wu G: Amino acids and immune function. Brit
J Nutr 2007, 98(2):237-252.
doi:10.1186/1471-2105-12-254
Cite this article as: Blanchet et al.: Fusion of metabolomics and
proteomics data for biomarkers discovery: case study on the
experimental autoimmune encephalomyelitis. BMC Bioinformatics 2011
12:254.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Blanchet et al. BMC Bioinformatics 2011, 12:254
http://www.biomedcentral.com/1471-2105/12/254
Page 12 of 12
